More about

Wet Age-Related Macular Degeneration

News
January 26, 2024
1 min read
Save

Pegcetacoplan for geographic atrophy receives negative opinion from European committee

The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on a marketing authorization application for pegcetacoplan, according to an Apellis Pharmaceuticals press release.

News
January 13, 2024
2 min watch
Save

VIDEO: Duker shares EyePoint pipeline progress

WAILEA, Hawaii — In this Healio video perspective from Hawaiian Eye/Retina 2024, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, discusses the phase 2 DAVIO 2 results for EYP-1901 for the treatment of wet AMD.

News
January 11, 2024
1 min watch
Save

VIDEO: Faricimab demonstrates reduction in pigment epithelial detachment

In this video, Esther M. Bowie, MD, discusses a post hoc analysis comparing faricimab and aflibercept for the reduction of pigment epithelial detachment in patients with wet age-related macular degeneration.

News
December 28, 2023
1 min read
Save

Medsan to provide testing for RetinalGeniX study on personalizing wet AMD care

RetinalGeniX has contracted with Medsan to provide diagnostic testing for a study on personalizing medical evaluations for patients with wet age-related macular degeneration.

News
December 13, 2023
4 min watch
Save

VIDEO: Novel VEGF inhibitor under development for wet AMD

ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Angelo Maria Minnella, MD, speaks about sozinibercept, a VEGF-C/D inhibitor under development for the treatment of wet age-related macular degeneration.

News
December 05, 2023
1 min read
Save

Phase 2 trial of EYP-1901 in wet AMD meets all endpoints

The phase 2 DAVIO 2 trial of EYP-1901 met all primary and secondary endpoints in patients with wet age-related macular degeneration, EyePoint Pharmaceuticals announced in a press release.

News
November 11, 2023
4 min watch
Save

VIDEO: AVD-104 shows stability, GA lesion size reduction in phase 2/3 trial

SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Mohamed Genead, MD, CEO of Aviceda Therapeutics, discusses a trial investigating AVD-104 for geographic atrophy secondary to age-related macular degeneration.

News
November 09, 2023
1 min read
Save

OnPoint receives investigational device exemption for pseudophakic capsular lens magnifier

OnPoint Vision has announced FDA investigational device exemption approval for its AccuraSee device, according to a press release.

News
November 04, 2023
1 min read
Save

Be mindful of anti-VEGF injection speed, volume in patients with severe glaucoma

SAN FRANCISCO — When administering anti-VEGF treatments to patients with wet age-related macular degeneration, diabetic macular edema or retinal vein occlusion who have severe glaucoma, be mindful of the speed and volume of injections.

News
November 03, 2023
1 min read
Save

Develop practice implementation strategy for integration of new retinal therapies

SAN FRANCISCO — It is important for ophthalmologists to understand FDA indications and develop a proper practice implementation strategy for new retinal drugs entering the market, according to a speaker here.

View more